Bio-Rad Laboratories stock (US09062X1037): sector focus as Elliott stake and price gains keep NYSE listing in view

Bio-Rad Laboratories shares on the New York Stock Exchange continue to trade firmly above USD 300 after an activist stake by Elliott Investment Management and recent price-target activity, keeping the United States-based life-science tools group in focus for investors tracking the health-care equipment sector.

Bio-Rad Laboratories shares on the New York Stock Exchange traded around the low-USD 300 range in late May, with a recent quote of about USD 303 per share and a market capitalization near USD 8.2 billion, according to Robinhood data as of 05/27/2026, underscoring the company’s profile as a mid-cap United States life-science tools provider.

The stock, listed under the ticker BIO on NYSE in the United States, has shown notable swings over the past year, with Investing.com data indicating a 52-week range of roughly USD 211 to USD 343 and a gain of more than 30 percent over that period as of late May 2026, reflecting renewed interest in the name.

In a development drawing fresh attention to the company from the U.S. market, activist investor Elliott Investment Management has built a sizable stake in Bio-Rad Laboratories and is preparing to press for changes, according to recent reporting cited by ZoomInfo, adding a corporate-governance angle to the investment case and potentially influencing strategic decisions.

On the sell-side side of the home market, Wells Fargo in the United States recently raised its price target on Bio-Rad Laboratories shares to USD 310 from USD 290 while maintaining an Equal Weight rating after a meeting with management, according to a Robinhood summary of analyst commentary dated 05/27/2026, signaling that mainstream U.S. research houses remain engaged on the stock even if their stance is not strongly directional.

The stock’s strong run earlier in 2026 has seen bouts of volatility, with TipRanks noting unusual trading patterns and highlighting that Bio-Rad’s prior rally has started to unravel at times, yet the shares remain materially higher than their 52-week low and continue to track broader U.S. health-care equipment valuations rather than small-cap biotech swings.

For German investors accessing U.S. equities via local platforms, Bio-Rad Laboratories is also available on venues such as Tradegate, where the shares typically follow NYSE pricing in euro terms, although liquidity and spreads tend to be driven primarily by the New York order book.

The stock traded at about USD 303 on 05/27/2026 on the New York Stock Exchange, according to Robinhood data as of 05/27/2026, providing the latest anchor point for the U.S. home-market price.

As of: 05/28/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: BIO
• Sector/industry: Life-science tools and diagnostics
• Headquarters/country: Hercules, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Research and clinical diagnostics instrumentation, reagents, and consumables
• Home exchange/listing venue: New York Stock Exchange (BIO)
• Trading currency: USD

Bio-Rad Laboratories: core business model

Bio-Rad Laboratories focuses on supplying specialized instruments, reagents, and consumables that support life-science research and clinical diagnostics laboratories worldwide, with demand tied closely to funding trends in biomedical research and routine testing volumes in hospitals and reference labs.

Industry trends and competitive position

Bio-Rad Laboratories operates within the global life-science tools and diagnostics sector, where long-term growth is supported by rising healthcare spending, increased prevalence of chronic diseases, and ongoing investments in molecular biology, proteomics, and genomics capabilities across research institutes and pharmaceutical companies.

The company competes with diversified groups such as Thermo Fisher Scientific, Danaher’s Veralto-related operations, and other specialized lab-equipment makers that offer a mix of instruments and consumables, and recent MarketBeat peer comparisons for Bio-Rad’s BIO.B share class versus Veralto highlight that scale, portfolio breadth, and recurring consumables revenue remain key differentiators as firms look to balance cyclical capital-equipment demand with more stable reagent sales.

Conclusion

Bio-Rad Laboratories remains an actively traded U.S. life-science tools stock on the New York Stock Exchange, with its share price holding above USD 300 and drawing added attention after Elliott Investment Management disclosed a significant stake and U.S. banks such as Wells Fargo refreshed their price targets.

Within the wider life-science tools and diagnostics sector, the company competes against large-scale peers focused on instruments and consumables, and the combination of activist involvement, sector dynamics, and home-market analyst engagement will be central to how the valuation and strategic narrative evolve from here.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.